Kymera to announce Phase 1 trial results for KT-579, a new oral drug for autoimmune diseases, on Oct 29, 2026

Kymera Therapeutics will report Phase 1 clinical trial results for KT-579, an oral small molecule targeting IRF5 to treat autoimmune diseases, on October 29, 2026. The trial involved healthy volunteers and tested single and multiple doses. KT-579 aims to modulate inflammatory pathways and could offer a new oral treatment option for conditions like lupus, rheumatoid arthritis, and inflammatory bowel disease. The announcement coincides with Kymera's third quarter 2026 financial results and will be shared via webcast and conference call.

As of Oct 29, 2026 03:11 WIB, Kymera Therapeutics Inc. (KYMR) shares are trading at USD 122.46 on Pluang, showing a 4.16% increase in the past day. The stock's market capitalization stands at $9.77 billion, with a trading volume of 827,854 shares. This notable price gain highlights investor interest coinciding with the company's upcoming announcement of Phase 1 trial results for KT-579.